Ebola is no one virus — it is actually a whole host of similar but distict viral agents.
And this Bundibugyo outbreak was both recognized very late, and in a very difficult remote rural geography — where endemic armed factional conflict rages. So a perfect storm of sorts. Here’s STAT+ — with the latest:
…Vaccines provide perhaps the clearest illustration of both the strengths and the limitations of current Ebola preparedness. The licensed rVSV-ZEBOV vaccine (Ervebo) transformed the response to outbreaks caused by EBOV remains one of the greatest achievements in infectious disease research. Because it targets the glycoprotein of EBOV, its effectiveness against Bundibugyo virus has long been uncertain. . . .
[But in the last few weeks…] emerging laboratory, immunologic, and animal data suggest that Ervebo may provide at least partial cross-protection against Bundibugyo virus. Although these findings remain preliminary and cannot establish clinical effectiveness, they raise important questions about whether Ervebo’s role should be reconsidered.
The new data prompted the WHO TAG-CVP to reassess the evidence on July 31. Given Ervebo’s extensive safety record, the group recommended evaluating it in a Phase 3 trial during the current outbreak without a preceding Phase 2 study. Important uncertainties remain, as much of the evidence is preliminary and Ervebo may offer greater protection against death than against symptomatic disease or transmission.. . .
Whether Ervebo ultimately proves to provide clinically meaningful protection against Bundibugyo virus is almost beside the point. The broader lesson is that these questions should have been asked and answered before a crisis — not during one of the largest Ebola outbreaks ever recorded. Preparedness cannot depend on assumptions about cross-protection between related viruses. It requires generating the evidence needed to guide vaccine policy before the next outbreak begins, not while lives hang in the balance.
The encouraging news is that science has responded with remarkable speed. Multiple Bundibugyo-specific vaccine candidates are now advancing through development, including monovalent and multivalent approaches intended to broaden protection across Ebola virus species.
The University of Oxford and the Serum Institute of India have launched the world’s first Phase 1 trial of a Bundibugyo-specific vaccine, while Moderna has begun a Phase 1 trial of an mRNA vaccine candidate. Together these efforts demonstrate how rapidly modern vaccine science can respond when sustained financing and political commitment exist. They also expose the cost of waiting for an emergency before asking whether our vaccines can confront the pathogen causing it….
Now you know — onward, resolutely.
नमस्ते
Powerline Lies... 